کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5630234 | 1580374 | 2016 | 7 صفحه PDF | دانلود رایگان |
- Anti-Neurofascin155 antibody was measured in CIDP patients by multiple methods.
- The diagnostic utility of human NF155-based ELISA for screening is validated.
- Western blot and CBA are useful for confirmation of positive results in ELISA.
- Development of the optimal treatment will require gathering of more information.
We aimed to validate the diagnostic utility of enzyme-linked immunosorbent assay (ELISA) for the detection of anti-neurofascin (NF) 155 antibody in 191 patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Human NF155-based ELISA clearly distinguished between anti-NF155 antibody-positive and -negative sera. Fifteen CIDP patients (8%) were IgG4 anti-human NF155 antibody-positive, which were confirmed by western blot, cell-based assay and immunohistochemical study. None of disease controls or healthy subjects had positive results. Clinical presentation of IgG4 anti-NF155 antibody-positive patients was consistent with those in previous reports. This ELISA combined with determination of the IgG4 subclass is useful in screening for anti-NF155 antibodies.
63
Journal: Journal of Neuroimmunology - Volume 301, 15 December 2016, Pages 16-22